Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accumulated Expenses (2016 - 2025)

Ironwood Pharmaceuticals' Accumulated Expenses history spans 16 years, with the latest figure at $11.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 20.33% year-over-year to $11.6 million; the TTM value through Dec 2025 reached $11.6 million, down 20.33%, while the annual FY2025 figure was $11.6 million, 20.33% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $11.6 million at Ironwood Pharmaceuticals, up from $5.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $23.6 million in Q4 2021 and bottomed at $1.3 million in Q3 2022.
  • The 5-year median for Accumulated Expenses is $8.9 million (2023), against an average of $9.8 million.
  • The largest annual shift saw Accumulated Expenses plummeted 93.48% in 2022 before it surged 555.67% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $23.6 million in 2021, then dropped by 29.14% to $16.7 million in 2022, then grew by 19.38% to $19.9 million in 2023, then decreased by 27.04% to $14.5 million in 2024, then fell by 20.33% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Accumulated Expenses are $11.6 million (Q4 2025), $5.4 million (Q3 2025), and $4.4 million (Q2 2025).